港府增購100萬劑復必泰疫苗 以推行第三劑新冠疫苗接種計劃
港府公布,已增購100萬劑復必泰疫苗以推行第三劑新冠疫苗接種計劃。連同已付運抵港的750萬劑,政府合共採購850萬劑復必泰疫苗。復星醫藥(02196.HK)已於今日(19日)早上將BioNTech製造並於德國Baxter廠房封裝的該批增購疫苗付運抵港。
新一批復必泰疫苗今日抵港後,工作人員隨即按既定程序,對有關疫苗進行檢查及核對,以確保疫苗符合產品規格及相關的冷鏈運輸標準。政府亦會把疫苗存放在經驗證的超低溫冷藏櫃,按藥廠指定的溫度妥善保存。這批疫苗的藥瓶標籤包含英文及簡體中文,但有關批次均由相同製造商及廠房以相同規格在德國製造及封裝。
政府已於11月3日公布,合資格的特定組別人士可由11月11日起免費接種第三劑新冠疫苗。(ek/a)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.